ME Therapeutics Holdings, Inc. (TSE:METX) has released an update.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ME Therapeutics Holdings Inc., a company specializing in immuno-oncology cancer therapies, has granted 250,000 stock options to a consultant, exercisable at $3.51 per share over the next three years. These options will vest in increments, with a hold period of four months and one day from the date of issuance. The company continues its focus on novel cancer treatments targeting immune suppression.
For further insights into TSE:METX stock, check out TipRanks’ Stock Analysis page.